Calibrate’s Medically-Supervised Commercial Obesity Treatment Program Combining Medication & Lifestyle Change Delivers Nearly 15% Weight Loss

People with obesity who participated in the Calibrate medically supervised weight loss program that combines GLP-1 medication and intensive lifestyle intervention achieved 14.8% average weight loss over a 12-month period. Consumers were able to sustain their weight loss for at least 18 months.

The outcomes of Calibrate’s program were published in The Obesity Society and presented at the annual forum during Obesity Week 2022. The study was led by Kim Boyd, M.D. and former World Obesity Federation President Donna Ryan, M.D.

The study followed 1,175 patients enrolled in a commercial obesity treatment program . . .